Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
Crispr Therapeutics AG (CRSP) Stock Price & Analysis
7,660 Followers
CRSP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$37.55 - $91.10
Previous Close$56.22
Volume1.08M
Average Volume (3M)1.53M
Market Cap
$4.77B
Enterprise Value$3.32B
Total Cash (Recent Filing)$1.69B
Total Debt (Recent Filing)$238.63M
Price to Earnings (P/E)-20.7
Beta1.15
Next Earnings
Jul 29, 2024EPS Estimate
-$1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding84,918,093
10 Day Avg. Volume1,559,385
30 Day Avg. Volume1,526,054
Standard Deviation0.20
R-Squared0.22
Alpha0.00405
Financial Highlights & Ratios
Price to Book (P/B)2.51
Price to Sales (P/S)23.73
Price to Cash Flow (P/CF)-12.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.94
Enterprise Value/Gross Profit8.94
Enterprise Value/Ebitda-25.36
Forecast
1Y Price Target
$79.17Price Target Upside40.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Crispr Therapeutics AG News
PremiumStock Analysis & Ideas
BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
PremiumStock Analysis & Ideas
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
Bulls Say, Bears Say
Bulls Say
Financial HealthWith over $2 billion in cash and cash equivalents, CRISPR Therapeutics is well-funded to support its ongoing development programs.
Market ExpansionVRTX's Casgevy launch in the Middle East is considered an important opportunity, potentially larger than the US market, with the region being underappreciated by investors.
Product Pipeline AdvancementCRISPR Therapeutics' CAR-T portfolio continues to progress with plans to initiate new studies and expected release of initial clinical data which could reveal potential clinical benefits.
Bears Say
Financial PerformanceNo revenues recognized for Casgevy sales in 4Q:23 reporting.
Market ExpectationsSales of Casgevy are anticipated to be much lower than consensus throughout 2024 as commercial uptake is expected to be challenging.
Stock ValuationThe approval of Casgevy is a major scientific achievement but it won't be used broadly enough to support the elevated valuation.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CRSP FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest stock price was $37.55 and its highest was $91.10 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Currently, no data Available
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is Jul 29, 2024 which is in 72 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on May 08, 2024. The company reported -$1.43 earnings per share for the quarter, missing the consensus estimate of -$1.361 by -$0.069.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -$1.52.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 84,918,090 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$1.43 in its last earnings report, missing expectations of -$1.361. Following the earnings report the stock price went up 0.488%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 556M.
---
Crispr Therapeutics AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$79.17 (40.82% Upside)
$79.17 (40.82% Upside)
Blogger Sentiment
Bullish
CRSP Sentiment 98%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 271.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.71%
12-Months-Change
Fundamentals
Return on Equity
-11.03%
Trailing 12-Months
Asset Growth
8.67%
Trailing 12-Months
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
---
CRSP Stock 12 Month Forecast
Average Price Target
$79.17
▲(40.82% Upside)
Technical Analysis
Best Analysts Covering CRSP
1 Year
1 Year Success Rate
18/36 ratings generated profit
1 Year Average Return
+24.28%
reiterated a buy rating 3 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +24.28% per trade.
---